Share this article
Share this article
PHILADELPHIA, Jan. 26, 2021 /PRNewswire/ Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma Multiforme (GBM), today announced publication of Phase 1b clinical trial results in
Clinical Cancer Research, a journal of the American Association for Cancer Research. The article Phase1b Clinical Trial of IGV-001 for patients with Newly Diagnosed Glioblastoma is available online.
IGV-001 is a first-in-class personalized immunotherapy that uses the patient s own tumor cells combined with an antisense molecule to induce a potent immune response. The treatment comprises irradiated autologous glioma cells with an antisense oligodeoxynucleotide directed at the IGF-1R (Insulin-like Growth Factor type one Receptor) named IMV-001. Delivered through an implantable and removable bio-diffusion chamber, antigenic products are released and initiate both an innate and adaptive response.